Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $39.44

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has earned an average recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $39.4444.

A number of research analysts have recently issued reports on the company. Wall Street Zen lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, December 29th. Truist Financial upped their price objective on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Leerink Partners lifted their target price on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, December 26th. Finally, Bank of America boosted their price target on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 3,302 shares of the stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the transaction, the insider directly owned 61,727 shares of the company’s stock, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Cecilia Jones sold 2,932 shares of the business’s stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the sale, the chief financial officer owned 37,394 shares in the company, valued at $1,013,003.46. The trade was a 7.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 37,005 shares of company stock worth $1,064,531 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bellevue Group AG grew its holdings in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after buying an additional 124,586 shares during the last quarter. Erste Asset Management GmbH raised its holdings in Agios Pharmaceuticals by 18.8% in the third quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company’s stock valued at $108,578,000 after buying an additional 438,411 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after acquiring an additional 2,049,287 shares in the last quarter. Commodore Capital LP boosted its position in shares of Agios Pharmaceuticals by 0.6% in the third quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock worth $93,859,000 after buying an additional 13,287 shares during the period. Finally, TCG Crossover Management LLC boosted its holdings in Agios Pharmaceuticals by 105.2% in the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after acquiring an additional 733,038 shares during the period.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $27.19 on Thursday. The firm’s fifty day moving average is $29.47 and its two-hundred day moving average is $35.55. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The firm has a market cap of $1.59 billion, a PE ratio of -3.88 and a beta of 0.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping the consensus estimate of ($1.93) by $0.15. The business had revenue of $12.88 million during the quarter, compared to the consensus estimate of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The business’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $16.22 earnings per share. Research analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.